21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients
21-Gene expression profile assay on core needle biopsies predicts responses to neoadjuvant endocrine therapy in breast cancer patients
复制标题
DOI：
10.1016/j.breast.2009.03.005
复制
发表时间：
2009-06-01
期刊：
影响因子：
3.9
通讯作者：
Yoshimura, Kenichi
中科院分区：
文献类型：
--
作者：
Akashi-Tanaka, Sadako;Shimizu, Chikako;Yoshimura, Kenichi
本研究检查了接受他莫昔芬或阿那曲唑前瞻性新辅助内分泌治疗 (NAET) 的绝经后雌激素受体阳性乳腺癌患者，以确定 21 基因复发评分 (RS) 是否可以预测 NAET 反应。 RS 评分由治疗前核心活检标本确定。尽管一半样本产生的 RNA 不足，但其余样本具有高度代表性。低 RS 的患者往往比那些中或高 RS 的患者反应更好 (n = 43)。他莫昔芬组和阿那曲唑组之间的 RS 反应率相似。低 RS 患者往往比所有中等或高 RS 患者有更好的无复发生存率 (RFS)（5y-RFS；分别为 100% vs. 84% 和 73%）。这些结果表明 RS 可以预测他莫昔芬或阿那曲唑对 NAET 的反应。由于这项试点研究的样本量较小，因此这些结果应在更大规模的研究中得到验证。 (C) 2009 Elsevier Ltd. 保留所有权利。
This study examined postmenopausal estrogen receptor-positive breast cancer patients who received prospective neoadjuvant endocrine therapy (NAET) with tamoxifen or anastrozole to determine if the 21-gene recurrence score (RS) predicts NAET responses. RS scores were determined from pretreatment core biopsy specimens. Although half of the specimens yielded insufficient RNA, the remaining samples were highly representative. Patients with a low RS tended to respond better than those with an intermediate or high RS (n = 43). Response rates by RS were similar between the tamoxifen and anastrozole groups. Patients with a low RS tended to have better relapse-free Survival (RFS) than those with ail intermediate or high RS (5y-RFS; 100% vs. 84% and 73%, respectively). These results suggest that RS predicts responses to NAET with tamoxifen or anastrozole. Because this pilot study examined a small sample size, these results should be validated in larger studies. (C) 2009 Elsevier Ltd. All rights reserved.